Drug Trial News

RSS

First-in-class drug shows promise as a safe and effective treatment for cannabis use disorder

A first-in-class drug engineered to selectively inhibit the signaling pathway of the cannabinoid receptor shows promise as a safe and effective treatment for cannabis use disorder (CUD), a condition where a person is unable to control their cannabis use, even though it's causing problems in their lives.

8 Jun 2023

Targeted therapy for non-small cell lung cancer provides benefit to patients after surgery

A clinical trial led by Yale Cancer Center shows that the drug osimertinib, a targeted therapy for non-small cell lung cancer, improved rates of survival and reduced risk of recurrence in patients after surgery.

7 Jun 2023

Electronic health records identified as hidden source of bias impacting clinical trials

Results of clinical trials are only as good as the data upon which they rest. This is especially true in terms of diversity -; if most people in a trial are from a certain race or socioeconomic group, then the results may not be broadly applicable.

7 Jun 2023

Patients with high-risk chronic lymphocytic leukemia may benefit from treatment with ibrutinib plus venetoclax

First-line ibrutinib (Imbruvica) plus venetoclax (Venclexta) led to high response and survival rates in patients with chronic lymphocytic leukemia (CLL) whether or not their cancer harbored high-risk genetic features typically associated with poor outcomes, according to results published in Clinical Cancer Research, a journal of the American Association for Cancer Research (AACR).

7 Jun 2023

Oral semaglutide outperforms other medications in type 2 diabetes treatment, significantly reducing HbA1c and body weight

Orally administered semaglutide shows significant efficacy in reducing HbA1c and body weight in patients with type 2 diabetes compared to other treatments. The study includes a large number of participants from multiple trials.

7 Jun 2023

Study assesses the safety, efficacy of using immune checkpoint inhibitors in patients with advanced kidney cancer

Patients with advanced kidney cancer are routinely given immune checkpoint inhibitors (ICIs) as first-line treatment.

5 Jun 2023

HER2-targeted antibody drug conjugate shows encouraging responses, long-lasting clinical benefit in several tumor types

In a new study of trastuzumab deruxtecan, a HER2-targeted antibody drug conjugate, researchers observed encouraging responses and long-lasting clinical benefit in several tumor types.

5 Jun 2023

Phase III ZUMA-7 trial: Patients with high-risk large B-cell lymphoma lived longer with axi-cel

Patients with early relapsed or refractory large B-cell lymphoma had significantly improved overall survival when treated with the chimeric antigen receptor (CAR) T cell therapy axicabtagene ciloleucel (axi-cel) when compared to the current standard-of-care chemoimmunotherapy, according to results of the Phase III ZUMA-7 trial reported by researchers from The University of Texas MD Anderson Cancer Center.

5 Jun 2023

Clinical trials demonstrate positive results from targeted therapy for patients with multiple tumor types with FGFR alterations

Three clinical trials led by researchers at The University of Texas MD Anderson Cancer Center demonstrated positive results from the targeted therapy erdafitinib for patients with multiple tumor types harboring FGFR alterations.

5 Jun 2023

SWOG Cancer Research Network clinical trial reveals potential new therapy for Stage 3 or 4 classic Hodgkin lymphoma

A Phase 3 trial has demonstrated that patients with advanced stage (3 or 4) classic Hodgkin lymphoma who underwent initial treatment with nivolumab, a PD-1 checkpoint inhibitor, and AVD chemotherapy (N-AVD) had a significantly lower risk of their cancer getting worse than patients treated with brentuximab vedotin, a monoclonal antibody, and AVD (BV-AVD) a year after starting treatment.

4 Jun 2023

Study shows efficacy and safety of novel FolRα-targeting antibody drug conjugate in recurrent epithelial ovarian cancer

Updated dose expansion data of the phase I STRO-002-GM1 study have been presented today by Ana Oaknin, Principal Investigator of the Vall d'Hebron Institute of Oncology's (VHIO) Gynecological Malignancies Group, on the ground at the 2023 Annual Meeting of the American Society of Clinical Oncology (ASCO), 2-6 June in Chicago, USA.

4 Jun 2023

Study of immunotherapy for brain cancer metastases shows promising results

In a phase 2 clinical trial of the immune checkpoint inhibitor pembrolizumab, investigators found that 42 percent of patients with metastatic brain cancer benefited from the therapy, with seven patients in the trial surviving longer than two years.

2 Jun 2023

Lupus Therapeutics announces three Phase 3 clinical trials testing new therapies for SLE and lupus nephritis

Lupus Therapeutics announced the start of a collaboration to conduct three Phase 3 clinical trials testing an investigational therapeutic ianalumab for systemic lupus erythematosus and lupus nephritis.

2 Jun 2023

Eye drops to slow the progression of nearsightedness in kids could be on the horizon

The results of a new clinical trial suggest that the first drug therapy to slow the progression of nearsightedness in kids could be on the horizon.

1 Jun 2023

Parkinson's disease drug ropinirole is safe and tolerable for ALS patients, early clinical trial shows

Amyotrophic lateral sclerosis (ALS), also known as Lou Gehrig's disease, is a fatal motor neuron disease that causes people to gradually lose control of their muscles.

1 Jun 2023

Treatment with modified lactic acid bacteria accelerates the healing of wounds, study shows

Complicated, hard-to-heal wounds are a growing medical problem and there are currently only two drugs approved with proven efficacy.

30 May 2023

Phase 3 studies for rectal, brain, and kidney cancers to be presented by Dana-Farber researchers at ASCO 2023

Several phase 3 studies conducted by researchers from Dana-Farber Cancer Institute show promising results for patients with rectal, brain, and kidney cancers. The results of these studies, along with dozens of others led by Dana-Farber researchers, will be presented at the 2023 Annual Meeting of the American Society of Clinical Oncology (ASCO) in Chicago.

26 May 2023

Treatment with luspatercept improves red blood cell counts in patients with myelodysplastic syndromes

Treatment with luspatercept improved red blood cell counts and erythroid responses compared to treatment with epoetin alfa in patients with myelodysplastic syndromes (MDS), allowing the majority to no longer require regular blood transfusions.

26 May 2023

New treatment protocol for brain hemorrhage improves survival chances without major disability

The George Institute for Global Health today announced data from the phase III INTERACT3 study demonstrating that a new combination of treatments for stroke due to intracerebral hemorrhage (ICH) significantly improves the chances of surviving without major disability.

26 May 2023

Novel vaccine offers hope for defeating epidemic meningitis by 2030

A trial of a new vaccine against meningococcal disease, a cause of meningitis and blood poisoning, has found that it is safe and induces a strong immune response across five strains of meningococcal bacteria: A, C, W, Y and X.

25 May 2023

Previous
1
...
18
19
20
21
22
23
24
...
1143
Next

Drug Trial News

First-in-class drug shows promise as a safe and effective treatment for cannabis use disorder

Targeted therapy for non-small cell lung cancer provides benefit to patients after surgery

Electronic health records identified as hidden source of bias impacting clinical trials

Patients with high-risk chronic lymphocytic leukemia may benefit from treatment with ibrutinib plus venetoclax

Oral semaglutide outperforms other medications in type 2 diabetes treatment, significantly reducing HbA1c and body weight

Study assesses the safety, efficacy of using immune checkpoint inhibitors in patients with advanced kidney cancer

HER2-targeted antibody drug conjugate shows encouraging responses, long-lasting clinical benefit in several tumor types

Phase III ZUMA-7 trial: Patients with high-risk large B-cell lymphoma lived longer with axi-cel

Clinical trials demonstrate positive results from targeted therapy for patients with multiple tumor types with FGFR alterations

SWOG Cancer Research Network clinical trial reveals potential new therapy for Stage 3 or 4 classic Hodgkin lymphoma

Study shows efficacy and safety of novel FolRα-targeting antibody drug conjugate in recurrent epithelial ovarian cancer

Study of immunotherapy for brain cancer metastases shows promising results

Lupus Therapeutics announces three Phase 3 clinical trials testing new therapies for SLE and lupus nephritis

Eye drops to slow the progression of nearsightedness in kids could be on the horizon

Parkinson's disease drug ropinirole is safe and tolerable for ALS patients, early clinical trial shows

Treatment with modified lactic acid bacteria accelerates the healing of wounds, study shows

Phase 3 studies for rectal, brain, and kidney cancers to be presented by Dana-Farber researchers at ASCO 2023

Treatment with luspatercept improves red blood cell counts in patients with myelodysplastic syndromes

New treatment protocol for brain hemorrhage improves survival chances without major disability

Novel vaccine offers hope for defeating epidemic meningitis by 2030

Small solutions for big problems in drug discovery and delivery

Professor Nancy Ip: Pioneering New Paths in Neurodegenerative Therapy

Utilizing process Raman in optimizing cultivated meat production

Latest News